What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
His main research concerns Internal medicine, Colorectal cancer, Prospective cohort study, Cancer and Oncology.
His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Surgery.
His Colorectal cancer research incorporates elements of Cancer research, Molecular pathological epidemiology, Microsatellite instability and Pathology.
His research integrates issues of Lower risk, Endocrinology, Incidence and Immunology in his study of Prospective cohort study.
His work in the fields of Cancer, such as Cetuximab, intersects with other areas such as Risk assessment.
Charles S. Fuchs interconnects Tumor microenvironment, Irinotecan, Fluorouracil and PTPRC in the investigation of issues within Oncology.
His most cited work include:
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial (1259 citations)
- Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment (993 citations)
- Prospective Study of Predictors of Vitamin D Status and Cancer Incidence and Mortality in Men (875 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Colorectal cancer, Oncology, Cancer and Prospective cohort study.
His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology, Endocrinology and Surgery.
His Colorectal cancer research is multidisciplinary, relying on both Lower risk, Cancer research, Molecular pathological epidemiology and Microsatellite instability.
His work deals with themes such as Pembrolizumab, Odds ratio, Chemotherapy, Pancreatic cancer and Adenocarcinoma, which intersect with Oncology.
His Cancer study incorporates themes from Aspirin, Gynecology, Disease and Cohort.
In his research, Epidemiology is intimately related to Cohort study, which falls under the overarching field of Prospective cohort study.
He most often published in these fields:
- Internal medicine (95.03%)
- Colorectal cancer (69.59%)
- Oncology (50.21%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (95.03%)
- Oncology (50.21%)
- Colorectal cancer (69.59%)
In recent papers he was focusing on the following fields of study:
Charles S. Fuchs focuses on Internal medicine, Oncology, Colorectal cancer, Cancer and Hazard ratio.
His Internal medicine study frequently intersects with other fields, such as Gastroenterology.
Charles S. Fuchs works mostly in the field of Oncology, limiting it down to topics relating to Pancreatic cancer and, in certain cases, Genome-wide association study and Single-nucleotide polymorphism.
His Colorectal cancer research is multidisciplinary, incorporating perspectives in Lower risk, Cancer research, Molecular pathological epidemiology and Microsatellite instability.
His study in Cancer is interdisciplinary in nature, drawing from both Aspirin, Placebo and Carcinoma.
His research integrates issues of Body mass index, Incidence, Survival rate, Quartile and Survival analysis in his study of Hazard ratio.
Between 2016 and 2021, his most popular works were:
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. (543 citations)
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial (396 citations)
- Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer (394 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
Charles S. Fuchs mainly focuses on Internal medicine, Colorectal cancer, Oncology, Cancer and Hazard ratio.
His study in Gastroenterology extends to Internal medicine with its themes.
The study incorporates disciplines such as Lower risk, Cancer research, Molecular pathological epidemiology and Microsatellite instability in addition to Colorectal cancer.
The various areas that he examines in his Oncology study include Immune checkpoint, Pancreatic cancer, Immunology, Germline and Carcinoma.
His Cancer study integrates concerns from other disciplines, such as Perioperative, Logistic regression and Group B.
Charles S. Fuchs combines subjects such as Survival rate, Whole grains, Quartile, Randomized controlled trial and Risk factor with his study of Hazard ratio.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
